CN103919777A - Medicinal composition for preventing and treating psoriasis and application thereof - Google Patents
Medicinal composition for preventing and treating psoriasis and application thereof Download PDFInfo
- Publication number
- CN103919777A CN103919777A CN201410183818.1A CN201410183818A CN103919777A CN 103919777 A CN103919777 A CN 103919777A CN 201410183818 A CN201410183818 A CN 201410183818A CN 103919777 A CN103919777 A CN 103919777A
- Authority
- CN
- China
- Prior art keywords
- palmatine
- pharmaceutical composition
- psoriatic
- active component
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicinal composition for treating psoriasis and an application thereof. The composition is prepared from an active component and auxiliaries, wherein the active component comprises palmatine or pharmaceutical salt thereof. The medicinal composition can play a good treatment effect in clinical treatment, and hardly has toxic or side effect on main organs of a human body, such as liver and kidney when being compared with a traditional medicament for treating psoriasis, cannot cause adverse response on the human body, and does not have potential safety problems if being used for a long time.
Description
Technical field
The invention belongs to medical technical field, particularly, relate in particular to the psoriatic pharmaceutical composition of a kind of control and application thereof.
Background technology
Psoriasis is a kind of common dermatosis, and the psoriatic cause of disease, pathogeny are still very not clear and definite at present, without specific treatment method, are one of diseases of department of dermatologry primary study yet.The treatment measure that psoriasis is conventional comprises: (1) external application therapy; (2) ultraviolet phototherapy; (3) injection methotrexate; (4) take retinoic acid medicine; (5) glucocorticoid treatment.External application for curing only can relief of symptoms, cures the symptoms, not the disease; Ultraviolet radiation can promote that skin lesion disappears, but has potential carcinogenesis; Methotrexate is chemotherapeutics, easily produces many side effect; Glucocorticoid is applicable to erythrodermic psoriasis, arthropathic psoriasis and psoriasis pustulosa, but prolonged application side effect is fairly obvious.
Find not yet have at present palmatine to treat psoriatic bibliographical information by retrieval domestic and foreign literature.
Summary of the invention
The inventor finds by the large quantity research to psoriatic clinical symptoms, use low dosage palmatine to there is beyond thought therapeutic effect to psoriasis, and do not affect patient's spirit, diet, sleep and body weight, and there is not potential safety issue in life-time service.Based on this achievement in research, the invention provides the psoriatic pharmaceutical composition of a kind of control and application thereof.
The object of the present invention is achieved like this:
The psoriatic pharmaceutical composition of a kind of control, is prepared from by active component and adjuvant, and wherein said active component comprises palmatine or its officinal salt.
Preferably, prevent and treat as mentioned above psoriatic pharmaceutical composition, wherein said active component is made up of palmatine or its officinal salt.
Preferably, prevent and treat as mentioned above psoriatic pharmaceutical composition, hydrochlorate, benzenesulfonic acid, tartrate and citrate that wherein said palmatine officinal salt is palmatine.
Further preferably, prevent and treat as mentioned above psoriatic pharmaceutical composition, wherein said pharmaceutical composition is injection, and described injection comprises injection, lyophilized injectable powder.Further, described medicine is preferably injection.Described injection is the normal saline solution of palmatine.
Estrogen phase mouse vagina epithelium and Kunming mouse tail scale epidermis be all generally acknowledged psoriasis conventional animal experimental model, and they have simulated respectively two aspects that psoriasis basic pathology changes: the too fast and parakeratosis of epidermal hyperplasia.The inventor utilizes this two animal experimental models, clinically psoriasis is had to the methotrexate of significant curative effect as positive control, has evaluated respectively the impact of palmatine on epithelium mitosis and granular layer formation.Experimental result shows, palmatine forms all and has a significant effect the granular layer of the epithelial mitosis of mouse vagina, mouse tail scale epidermis.Therefore, the present invention also provides a kind of pharmaceutical applications, that is: palmatine or its officinal salt application in the psoriatic medicine of preparation control.
Compared with prior art, the pharmaceutical composition tool the present invention relates to has the following advantages and marked improvement: using natural active matter palmatine as the psoriatic medicine for the treatment of, especially control low dosage administration, in clinical treatment, can realize reasonable therapeutic effect, control the scope that patient's opportunistic infection can be born at body simultaneously, than the psoriatic medicine of traditional treatment, human body major organs is not almost had to toxic and side effects as liver, kidney, can not cause human body untoward reaction, there is not potential safety issue in life-time service simultaneously.
Detailed description of the invention
Estrogen phase mouse vagina epithelium and Kunming mouse tail scale epidermis be all generally acknowledged psoriasis conventional animal experimental model, and they have simulated respectively two aspects that psoriasis basic pathology changes: the too fast and parakeratosis of epidermal hyperplasia.The inventor utilizes this two animal experimental models, clinically psoriasis is had to the methotrexate of significant curative effect as positive control, has evaluated respectively the impact of palmatine on epithelium mitosis and granular layer formation.Experimental result shows, palmatine forms all and has a significant effect the granular layer of the epithelial mitosis of mouse vagina, mouse tail scale epidermis.Concrete process of the test is as described in following embodiment.
embodiment 1 palmatine hydrochloride is on the mitotic impact of estrogen phase mouse vagina epithelial cell
Get 30 of clean level KM female mices, body weight 20-22g, for three days on end lumbar injection diethylstilbestrol, each 0.2mg, make mouse vagina epithelium in the estrogen phase, model mice was divided into following three groups at random in the 4th day: model control group, positive controls, palmatine intervention group, 10 every group.Palmatine intervention group lumbar injection palmatine hydrochloride, is 20mg/kg by each every the dosage of Mouse Weight, model control group lumbar injection 0.2ml normal saline, and positive controls lumbar injection methotrexate 100mg/kg, injects 3 days, once a day continuously.Impact for fear of circadian rhythm on cell mitogen, it is at 8 o'clock in the morning that last is injected unified time, gave every mouse peritoneal injection colchicine 2mg/kg at 9 o'clock in the morning, after 6h, disconnected neck is put to death mice, cut vagina tissue, fix with 10% formalin solution, paraffin embedding, HE dyeing, under optical microscope, count the mitosis number in 300 basal cells, convert out the mitosis number in every 100 basal cells, be called mitotic index, respectively organize the epithelial mitotic index of mouse vagina.
Experimental result shows, under microscope, visible mouse vagina epithelium is multilamellar epithelium, occurs keratinization, confirms to belong to the vagina epithelium of estrogen phase.The epithelial mitotic index of each group mouse vagina is in table 1.As seen from Table 1, the epithelial mitotic index of mouse vagina of positive controls and palmatine intervention group is very significantly lower than model control group, have utmost point significant difference (
p< 0.01).
The comparison of the each group of table 1 mouse vagina epithelial cell mitotic index
With model control group comparison,
▼ p< 0.05,
▼ ▼ p< 0.01.
the impact that embodiment 2 palmatine hydrochlorides form mouse tail scale granular layer of epidermis
Get 30 of clean level KM mices, male and female half and half, body weight 20-22g, is divided into following three groups at random: model control group, positive controls, palmatine intervention group, 10 every group.Palmatine intervention group lumbar injection palmatine hydrochloride, be 20mg/kg by each every the dosage of Mouse Weight, model control group lumbar injection 0.2ml normal saline, positive controls lumbar injection methotrexate 100mg/kg, once a day, inject continuously 15 days disconnected neck execution mices afterwards, get the about 1.8cm of Mus back range root place one rectangular skin, fix with 10% formalin solution, paraffin embedding, HE dyeing, at the tail scale of the each mice of optical microphotograph Microscopic observation, all scale epidermises have the granular cell person who embarks on journey continuously, be called the scale that has granular layer to form, count the scale number that has granular layer in every 100 scales, each group of data are compared, and take statistics is processed.
Experimental result is in table 2, has scale number that granular layer forms very significantly more than model control group in every 100 the Mus tail scales of positive controls and palmatine intervention group mice, have utmost point significant difference (
p< 0.01).
The comparison of the each group of table 2 mouse tail scale granular layer of epidermis formational situation
With model control group comparison,
▼ p< 0.05,
▼ ▼ p< 0.01.
Claims (5)
1. the psoriatic pharmaceutical composition of control, is prepared from by active component and adjuvant, it is characterized in that: described active component comprises palmatine or its officinal salt.
2. prevent and treat according to claim 1 psoriatic pharmaceutical composition, it is characterized in that: described active component is made up of palmatine or its officinal salt.
3. prevent and treat according to claim 1 psoriatic pharmaceutical composition, it is characterized in that: hydrochlorate, benzenesulfonic acid, tartrate and citrate that described palmatine officinal salt is palmatine.
4. described in claim 1 or 2 or 3, prevent and treat psoriatic pharmaceutical composition, it is characterized in that: described pharmaceutical composition is injection, and described injection comprises injection, lyophilized injectable powder.
5. palmatine or its officinal salt application in the psoriatic medicine of preparation control.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410183818.1A CN103919777A (en) | 2014-05-04 | 2014-05-04 | Medicinal composition for preventing and treating psoriasis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410183818.1A CN103919777A (en) | 2014-05-04 | 2014-05-04 | Medicinal composition for preventing and treating psoriasis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103919777A true CN103919777A (en) | 2014-07-16 |
Family
ID=51138325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410183818.1A Pending CN103919777A (en) | 2014-05-04 | 2014-05-04 | Medicinal composition for preventing and treating psoriasis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919777A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505362A (en) * | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406564A (en) * | 2007-10-08 | 2009-04-15 | 江苏中康药物科技有限公司 | External-use Chinese medicinal composition formulation and uses thereof |
| CN102786518A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Palmatine hydrochloride crystal B substance, its preparation method, and its applications in medicines and healthcare products |
-
2014
- 2014-05-04 CN CN201410183818.1A patent/CN103919777A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406564A (en) * | 2007-10-08 | 2009-04-15 | 江苏中康药物科技有限公司 | External-use Chinese medicinal composition formulation and uses thereof |
| CN102786518A (en) * | 2011-05-18 | 2012-11-21 | 中国医学科学院药物研究所 | Palmatine hydrochloride crystal B substance, its preparation method, and its applications in medicines and healthcare products |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020505362A (en) * | 2017-01-19 | 2020-02-20 | ティダブリューアイ・バイオテクノロジー・インコーポレイテッドＴＷＩ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
| EP3570835A4 (en) * | 2017-01-19 | 2021-03-03 | TWI Biotechnology, Inc. | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| CN101744895A (en) | Medical preparation for treatment of rheumatism, lumbar vertebra disease and cervical spondylosis | |
| CN103285155A (en) | Traditional Chinese medicine composition for treating eczema and dermatitis | |
| CN103656111A (en) | Internal traditional Chinese medicine preparation for preventing and treating diabetic foot and preparation method thereof | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN102579999B (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN102240260B (en) | Medicament for treating colpoxerosis and preparation method thereof | |
| CN105125984B (en) | A kind of aqueous Chinese medicine plaster for external application for treating infantile cough | |
| CN103142959A (en) | Medicament for treating urticaria | |
| CN103919777A (en) | Medicinal composition for preventing and treating psoriasis and application thereof | |
| CN101953889A (en) | Compound ceftiofur suspension emulsion injection and preparation method thereof | |
| CN103041251A (en) | Traditional Chinese medicine composition for treating chronic bronchitis | |
| CN103463276B (en) | Mammary gland hyperplasia treatment drug composition and preparation method thereof | |
| CN101884756B (en) | Pharmaceutical composition with functions of expelling wind and removing dampness and activating collaterals and relieving pain, preparation method, preparation and application thereof | |
| CN102335391B (en) | Fumigant for treating psoriasis | |
| CN104510955A (en) | Traditional Chinese medicine formula for treating beriberi | |
| CN102648956A (en) | Traditional Chinese herbal medicament for treating breast cancer and preparation method thereof | |
| CN102836152A (en) | Application of physalin B in preparation of medicine for curing and/or preventing schistosomiasis | |
| CN109223890A (en) | A kind of composition for premature ejaculation sex dysfunction | |
| CN101618205B (en) | Medicine composition for treating cold in types of wind cold and exterior syndrome of deficiency and preparation method thereof | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN104000894A (en) | Pharmaceutical composition accelerating healing of burn and scald wounds and application thereof | |
| CN105560837A (en) | Drug for treating skin injuries and preparation method thereof | |
| CN102961722B (en) | Traditional Chinese medicine composition for treating senile constipation | |
| CN105343094A (en) | Pharmaceutical composition resisting cancer cell migration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140716 |